Financials in GBp. Standardized financial statements.
A compact view of how BioPharma Credit PLC turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £140.06M | £124.46M | £135.74M | £184.25M | £87.97M | £91.35M | £124.12M | £78.72M | £33.65M |
| Revenue Growth? | +12.5% | -8.3% | -26.3% | +109.4% | -3.7% | -26.4% | +57.7% | +133.9% | 0.0% |
| Cost of Revenue? | £25.70M | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Gross Profit? | £114.36M | £124.46M | £135.74M | £184.25M | £87.97M | £91.35M | £124.12M | £78.72M | £33.65M |
| Gross Margin? | +81.7% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | -£15.33M | £2.28M | £27.28M | £1.93M | £3.01M | £2.22M | £1.79M | £8.57M | £6.48M |
| Operating Income? | £129.69M | £122.18M | £108.46M | £182.31M | £84.96M | £89.14M | £122.33M | £70.15M | £27.12M |
| EBITDA? | £129.73M | £122.18M | £0 | £0 | £0 | £0 | £0 | £0 | £0 |
| Income Before Tax | £129.73M | £122.18M | £108.45M | £182.31M | £84.96M | £89.14M | £122.33M | £70.15M | £27.16M |
| Income Tax Expense | £0 | £0 | £0 | £0 | £0 | £0 | £0 | -£161,141 | £40,286 |
| Net Income? | £129.73M | £122.18M | £108.45M | £182.31M | £84.96M | £89.14M | £122.33M | £70.15M | £27.16M |
| EPS? | £0.11 | £0.10 | £0.08 | £0.13 | £0.06 | £0.06 | £0.09 | £0.07 | £0.04 |
| Diluted EPS? | £0.11 | £0.10 | £0.08 | £0.13 | £0.06 | £0.06 | £0.09 | £0.07 | £0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality